Topol, Microsoft Say AI Cuts Diagnostic Costs as Health Systems Stall

Can AI help build a healthier future? — Researchers across the Microsoft research community

Researchers across the Microsoft research community

While agentic AI models nearly double physician diagnostic accuracy at lower costs, clinical deployment stalls because single-year insurance cycles eliminate economic incentives for preventative care.

AI-assisted summary of Can AI help build a healthier future? — original source. Check the original for full context.

Source published:

Key ideas

  • A Microsoft-led Science cover study showed that modeling sequential clinical cognition in an AI agent nearly doubled the diagnostic accuracy of generalist physicians while simultaneously reducing total testing costs. (5:00)
  • Despite over 44 randomized controlled trials in colonoscopy and trials with over 100,000 participants in mammography, proven computer vision AI tools face an implementation gap driven by institutional conservatism and thin operating margins. (5:00)
  • Token serving costs on fixed models are plummeting by 4x to 10x annually, positioning computation as an active-learning guide to minimize expensive physical wet-lab iterations. (30:00)
  • Eric Horvitz predicts that within ten years, AI will help transform multiple fatal cancers into manageable chronic conditions and substantially delay the onset of Alzheimer's disease. (50:48)

Detailed notes

## Background This episode of the podcast series The Shape of Things to Come was published by researchers across the Microsoft research community on November 17, 2026, via RSS and web audio. Hosted by Microsoft Research lead Doug Burger, the discussion features Microsoft Principal Research Manager Ava Amini, Microsoft Chief Scientific Officer Eric Horvitz, and physician-scientist Eric Topol of Scripps Research exploring what artificial intelligence can enable in medicine and how to achieve those breakthroughs.

## TL;DR The panel examines the transformative convergence of AI, multiscale biology, and clinical medicine, tracing how agentic models and generative tools are shifting diagnostic reasoning, drug discovery, and biological simulation. While AI demonstrates superhuman diagnostic accuracy and deep administrative relief through ambient clinical scribes, its real-world implementation is severely constrained by health system inertia, economic misalignments, and the physical bottlenecks of wet-lab validation. Looking toward the horizon, the experts contrast silicon-style abstractions with biological complexity, highlighting breakthroughs in immunome profiling, dynamic activity-first datasets, and synthetic biology. Ultimately, the guests express radical optimism, forecasting that AI will turn terminal cancers into manageable conditions, delay or avert neurodegenerative diseases like Alzheimer's, and make future medical practice unrecognizable compared to today.

## Atmosphere & style The conversation carries an intellectually charged, visionary, and collegiate atmosphere, blending cutting-edge scientific rigor with effortless personal camaraderie. Doug Burger steers the dialogue with warm, self-deprecating wit—frequently poking fun at his own computer-hardware biases—while Eric Topol, Eric Horvitz, and Ava Amini provide deep, measured perspectives spanning clinical reality and theoretical machine learning. Listening in feels like sitting at a high-level research symposium where pragmatic frustrations over healthcare conservatism smoothly give way to radical, infectious optimism about rewriting the very foundations of human biology.

## Bulletin - `05:00` A Microsoft-led Science cover study showed that modeling sequential clinical cognition in an AI agent nearly doubled the diagnostic accuracy of generalist physicians while simultaneously reducing total testing costs. - `05:00` Despite over 44 randomized controlled trials in colonoscopy and trials with over 100,000 participants in mammography, proven computer vision AI tools face an implementation gap driven by institutional conservatism and thin operating margins. - `30:00` Token serving costs on fixed models are plummeting by 4x to 10x annually, positioning computation as an active-learning guide to minimize expensive physical wet-lab iterations. - `50:48` Eric Horvitz predicts that within ten years, AI will help transform multiple fatal cancers into manageable chronic conditions and substantially delay the onset of Alzheimer's disease.

## Key takeaways - `00:00` Medicine and biosciences possessed a digital head start for deep learning due to early standardization, including curated protein repositories and widespread electronic health records. - `05:00` Evaluating medical AI by simulating interactive clinician cognition outperforms static vignette tests, demonstrating that agents can balance diagnostic value against procedural cost. - `10:00` Clinical AI adoption lags behind research validation largely due to low hospital profit margins and a lack of organized consumer or physician advocacy for validated tools. - `12:12` Biological modeling faces a multiscale hierarchy spanning molecular dynamics, single cells, tissues, and organ systems that cannot easily be bridged using silicon-style clean abstractions. - `20:00` Whole-patient models that synthesize electronic health records with risk scores are likely to deliver clinical value well before complete virtual cell models are achieved. - `20:00` Single-year commercial insurance contracts in the United States disincentivize preventative AI investments that only yield economic returns decades later. - `22:50` Effective drug discovery does not require deterministic, atom-by-atom interpretability; instead, models need to generate actionable hypotheses testable in wet labs over one- to two-year horizons. - `25:40` Diagnostic errors account for an estimated 800,000 deaths and serious disabilities annually in the United States, providing a critical operational target for diagnostic AI. - `25:40` Ambient clinical scribes and empathetic patient-facing conversational models are helping alleviate physician administrative burdens and restore doctor-patient face time. - `30:00` Physical wet labs will remain an unavoidable bottleneck, making AI's primary value the guidance of experimental spend toward areas of highest informational yield. - `34:58` Life sciences lack comprehensive, longitudinal multimodal datasets comparable to the Protein Data Bank, making dynamic, activity-first datasets the critical missing asset for foundation models. - `40:00` AI-assisted profiling of the human immunome and functional thymus retention is overturning textbook dogmas and refining biological versus chronological age tracking. - `43:20` Targeting systemic biological aging mechanisms and epigenetic decay holds higher therapeutic leverage than tackling isolated late-onset diseases individually. - `47:30` Synthetic biology is transitioning from simple genetic logic gates in bacteria toward multimodal generative foundation models that synthesize de novo proteins from natural language prompts. - `50:48` Advances in real-time embryonic genome editing and generative modeling are rapidly compressing the timeline toward fully programmable biological systems. - `55:00` Long-term medical AI progress aims to shift healthcare entirely from reactive treatment to proactive prevention of complex conditions like cancer and Alzheimer's disease.

## Detailed walkthrough ### `00:00` Framing the Frontier: AI at the Intersection of Biology and Medicine

Doug Burger opens the episode of *The Shape of Things to Come*, setting out to venture to the bleeding edge of AI capabilities and explore how they will alter the future of healthcare, biological understanding, and medical breakthroughs. To tackle these themes, he brings together a trio of experts from medicine, biology, and machine learning:

- **Eric Horvitz**, Microsoft’s Chief Scientific Officer, an MD/PhD whose foundational work has shaped machine learning for decades (with Burger joking, “How you spend all those years in school, I have no idea”). - **Eric Topol**, Executive Vice President of Scripps Research—the largest nonprofit biomedical research institute in the United States—who has authored four books and published over 1,300 peer-reviewed papers, an output Burger characterizes as “shockingly productive.” - **Ava Amini**, a Principal Research Manager at Microsoft Research and co-lead of Project Ex Vivo, a joint initiative between Microsoft and the Broad Institute focused on defining, engineering, and targeting cancer cell states.

Setting the stage, Burger observes an accelerating disruption across the field: AI models are uncovering structural biology, extracting actionable medical representations, and even enabling anecdotal reports of cancer scientists designing their own therapeutic interventions. Horvitz traces the roots of this inflection point to decades of data accumulation. Unlike areas caught unprepared by deep learning, medicine and biosciences benefited from early digital standardization, including decades of curated protein structures and the widespread adoption of electronic health records (EHRs).

This established digital backbone allowed both discriminative and generative AI models to hit the ground running over the last five to eight years. Horvitz points out that while the emergence of systems like AlphaFold captured global attention, it represented only the visible crest of a much larger wave now transforming experimental design, data interpretation, and hypothesis generation. As Eric Horvitz puts it:

> “AlphaFold's breakthrough was tip of the iceberg, and we see just a whole, in some ways, a crest and a crashing of a wave of possibilities now when it comes to experimental platforms, experimental design, data interpretation in the biosciences, hypothesis generation, I should say, as an assistant and a companion to scientific reasoners and human scientists.”

`05:00` Benchmarking Medical Cognition and the Clinical Efficiency Paradox

```mermaid flowchart TD accTitle: Sequential Diagnosis Workflow in Clinical Cognition accDescr: An AI agent acts as a clinician, iteratively asking questions, selecting diagnostic tests based on cost and value, and reaching a final diagnosis.

subgraph AmbInput["Clinical Intake"] A["Ambulatory Patient Presentation"] end

subgraph AgentLoop["Agentic Medical Cognition Loop"] B["Formulate Differential Hypotheses"] C["Evaluate Next Action\n(Questions or Tests)"] D["Balance Information Value vs. Financial/Physical Cost"] B --> C C --> D D -->|Gather new data| B end

subgraph FinalStep["Resolution"] E["Convergent Diagnostic Decision"] F["Initiate Targeted Therapy"] end

A --> B D -->|Sufficient certainty| E E --> F ```

Horvitz describes a recent *Science* cover article produced by his team at Microsoft that reframes AI diagnostic evaluation. Historically, diagnostic benchmarks simply fed an entire, completed clinical vignette to a model and graded its static differential diagnosis. Horvitz’s team pivoted to modeling active "medical cognition." By placing the model inside the interactive posture of an ambulatory clinician, the system begins with minimal initial presentation data. The agent must sequentially deduce what questions to ask, weigh the diagnostic information value of laboratory or imaging tests against their financial and procedural costs, and determine the exact inflection point at which to stop testing and commit to a convergent diagnosis to initiate treatment. When evaluated against human generalist physicians, frontier language models demonstrated remarkable aptitude in orchestrating this sequential problem-solving under real-world constraints.

Eric Topol reinforces the significance of this work from his vantage point outside Microsoft, highlighting that the study broke an entrenched pattern where healthcare AI is predominantly deployed for administrative billing optimization or "upcoding" that drives up expenses. This work offered the first agentic demonstration that nearly doubled diagnostic accuracy over generalist physicians while simultaneously reducing diagnostic costs—an outcome Topol likens to an impossible ideal: “It's kind of like eat more, weigh less, or it tastes better.”

At the same time, Topol flags a frustrating clinical paradox: medicine has become mesmerized by the "shiny object" of four-year-old generative AI while dragging its feet on mature, deeply validated deep learning applications in computer vision. Despite robust evidence—such as randomized trials covering more than 100,000 women in mammography and 44 randomized trials in colonoscopy—the healthcare sector has failed to broadly harvest the superhuman features AI extracts from retinal scans, electrocardiograms (ECGs), and chest X-rays. Topol argues that fully capitalizing on this missed foundation is critical because it represents the essential substrate for the next true frontier: "whole patient models" that fuse raw medical images with longitudinal EHR records, genomics, proteomics, and exposome data to forecast disease trajectories for individual patients.

- Microsoft's *Science* cover paper shifted AI evaluation from passive, complete-case diagnostic classification to an agentic sequential diagnosis process that mimics clinician cognition. - The agentic architecture nearly doubled the diagnostic accuracy of generalist physicians while driving down total testing costs. - Over 44 randomized clinical trials validate AI in colonoscopy, and trials exceeding 100,000 participants validate it in mammography, yet practical clinical implementation continues to lag behind research validation.

`10:00` The Implementation Gap and Healthcare System Inertia

The discussion centers on the disconnect between breakthrough medical AI research and actual clinical deployment. While AI models can evaluate counterfactual "what-if" scenarios to prevent or defer disease using rich health data sets, Eric Topol warns that medicine remains stagnant at the bedside: “I'm still waiting for that to happen, in medicine to say the least.” When Doug Burger asks what the research and clinical communities are missing, Topol points directly to execution and deployment rather than a lack of compelling science. Groundbreaking, peer-reviewed, randomized real-world trials are consistently published in top-tier journals, yet their findings never reach patient care.

According to Topol, health systems offer numerous excuses, but the underlying barrier is cultural and economic conservatism. Hospitals and health networks operate on razor-thin financial margins, making leadership hesitant to invest in technologies they do not fully understand or trust. Compounding this inertia is a surprising lack of advocacy from both clinicians and the public. Topol highlights mammography screening as a stark example: despite proven AI models that improve diagnostic accuracy, almost no women in the United States receive state-of-the-art AI interpretation unless they pay out of pocket or belong to niche networks. As Topol puts it:

> “You know, one thing that's noteworthy is the physicians are not clamoring for these advances. I mean, if you're a woman undergoing mammography and you don't get state of the art AI, which almost no women in the United States do, you'd think you might run a revolt, or you have to pay for it to get that interpretation in a very limited network.”

- **Real-world trial disconnect:** High-quality randomized controlled trials supporting AI tools are languishing in academic journals instead of being integrated into clinical workflows. - **Economic constraints:** Low operating margins across health systems disincentivize capital investment in unproven, novel infrastructure. - **Absence of grassroots demand:** Neither physicians nor patients are actively demanding or revolting over the lack of access to validated, life-saving AI diagnostics.

---

`12:12` Multiscale Biology and the Challenge of Real-World Implementation

Turning to the biosciences side of AI, Ava Amini emphasizes that while excitement, capital investment, and optimism are currently surging, biological AI faces the exact same bottleneck as medicine: practical implementation. Building predictive and generative models for biological systems means very little if researchers cannot pinpoint the specific problems they solve or successfully integrate them into wet-lab experimental workflows. To address this friction, Microsoft is collaborating directly with the Broad Institute, co-designing research from the bottom up to ensure machine learning methods genuinely interface with laboratory biology.

Beyond adoption, Amini identifies an enormous computational and modeling hurdle: biology is fundamentally a multiscale hierarchy. Living systems function across drastically different layers of organization—from molecular dynamics to single cells, structured tissues, coordinated organ systems, and ultimately the whole organism. Each layer interacts dynamically to produce coherent physiological function. Bridging these distinct scales so that molecular details yield actionable insights at the whole-patient level is an AI problem with almost no equivalent in other engineering domains. Consequently, AI researchers face fundamental questions regarding data representation, data diversity, and deciding whether to pursue depth on narrow, high-priority diseases versus broad platform democratization.

> “And really the question in my mind is, what are these actually going to solve? What questions can we deploy them towards? How are we going to implement them? How will they be adopted by experimental scientists and integrated into our workflows? And that is a gap that I think still the community needs to bridge.”

```mermaid flowchart TD accTitle: Multiscale Biological Hierarchy in AI Modeling accDescr: A hierarchy illustrating biological scales from molecules to the whole organism and patient insights.

subgraph MolecularAndCellular["Microscopic Scales"] M["Molecular Level\n(Proteins, DNA, chemical compounds)"] C["Single-Cell Level\n(Cellular phenotypes & states)"] M --> C end

subgraph TissueAndOrgan["Macroscopic Systems"] T["Tissue Level\n(Cell-cell organization)"] O["Organ Systems\n(Physiological networks)"] C --> T T --> O end

subgraph WholePatient["Clinical Integration"] P["Whole Patient Model\n(Organismal health & disease)"] O --> P P --> I["Actionable Medical Insights\n& Counterfactual Scenarios"] end ```

- **The deployment dilemma:** AI for biology risks producing powerful generative architectures that lack concrete, deployable experimental utility. - **Collaborative co-design:** The partnership between Microsoft and the Broad Institute aims to integrate machine learning and laboratory workflows from inception. - **Cross-scale computation:** Translating data across biological strata—from molecular interactions up to organ-level human pathology—demands novel representation techniques and data diversity strategies.

---

`15:18` Silicon Abstractions vs. Biological Complexity

Doug Burger introduces a philosophical and architectural comparison drawn from his background as a computer architect. In chip design, engineers place billions of circuits onto a postage-stamp-sized piece of silicon. Although the physics inside the PN junctions and transistor gates are governed by messy, stochastic quantum mechanics and electrostatic forces, engineers successfully tame that disorder by constructing rigid, deterministic hierarchies of clean abstraction. Burger asks the panel whether biology can ever be mapped into a similar stack of clean, predictable abstractions where every component is fully understood, or if biological systems are doomed to remain irreducibly messy.

Eric Horvitz points out an ironic symmetry: even in computing, once researchers deploy massive, deep generative models across those pristine silicon architectures, algorithmic behavior becomes complex, emergent, and stochastic once again. Turning to human physiology, Horvitz argues that the body is an extraordinarily complex, multiscale dynamical system. While we may never achieve atomic-level deterministic certainty across all biological layers, AI can manage this complexity by discovering causal models, developing interpretability methods, and untangling both intra-level and cross-level dynamics. Burger lightens the academic exchange with a joke, reducing Horvitz’s nuanced response to a single bit of information:

> “My sense is carrying the analogy forward to a multi-scale dynamical system, the human body, is that there's going to be very high degrees of complexity when it comes to the dynamics and interactions of parts at different levels of abstraction.”

> “I think that was a no,” Burger quipped. “I did a low-rank approximation on Eric Horvitz and got one. Sorry to boil you down.”

- **The computer architecture parallel:** Clean abstractions allow humans to design billions of functioning components despite underlying quantum and electrostatic noise. - **The return of stochasticity:** Modern generative AI reintroduces non-deterministic, messy dynamics on top of deterministic hardware stacks. - **Causal modeling in biology:** Horvitz emphasizes that managing biological complexity requires principled causal models and interpretability tools rather than brute-force atomic accounting.

---

`18:41` The Virtual Cell vs. The Virtual Patient

Eric Topol challenges the pessimistic view that biology will forever remain an untameable, messy black box. He points out that the scientific community is already making serious progress toward creating a "virtual cell"—an in silico simulation capable of predicting how a single cell will react to arbitrary perturbations and genetic interventions. If realized, virtual cell models will crack open previously opaque mechanisms of cellular biology.

However, Topol acknowledges that progressing from a single-cell model to a "virtual human" or "virtual patient" remains a massive, unresolved leap. Current clinical tools illustrate just how weak medicine's holistic models currently are. While clinicians can calculate a polygenic risk score or sequence an individual's entire genome to identify an elevated risk for complex conditions such as coronary heart disease, they still cannot predict whether, when, or how that disease will actually manifest in the individual patient.

> “Firstly, as you know, there's a lot of interest in creating the virtual cell, where you would be able to do any number of perturbations and predict its response, unravel a lot of biology.”

- **Virtual cell ambitions:** Simulating cellular perturbation responses is within reach and represents the first major milestone in formalizing biological abstractions. - **The virtual patient gap:** Medicine currently lacks the cross-scale models needed to connect genomic or polygenic risk predictions to concrete clinical outcomes for individual patients.

`20:00` Whole-Patient Models and the Disincentives for Prevention

The discussion opens with the realization that simply telling a patient they are at risk for a disease at some vague point—whether at age 50 or 90—is fundamentally unhelpful. Existing models trained on electronic health records (EHR) paired with lifestyle factors or polygenic risk scores are already beginning to provide actionable timing and context, even before medicine has gathered deep, longitudinal multi-omic data at scale. Because of this, mature whole-patient models are likely to arrive well before complete virtual cell models. While a patient model cannot simulate every possible cellular perturbation across the body's trillions of diverse cells, its ultimate clinical value lies in shifting healthcare beyond passive risk assessment toward genuine prevention.

```mermaid flowchart TD accTitle: US Healthcare Prevention Disincentive Model accDescr: Diagram illustrating how short insurance cycles create structural disincentives for preventative medicine in the US compared to single-payer models.

subgraph US_System["United States Model"] A["1-Year Insurance Cycles"] --> B["Short-Term Financial Interests"] B --> C["Disincentive to Fund Long-Term Prevention"] C --> D["Reactive Sick-Care at Hospitals"] end

subgraph Alternative_System["Unified / International Systems"] E["Long-Term Population Health Mandate"] --> F["Reduced Long-Term Economic Burden"] F --> G["Structural Incentive to Invest in Preventative AI"] end ```

Doug Burger notes that at a recent conference exploring the intersection of AI and medicine, speakers argued that the prevailing economic framework of healthcare is structurally incompatible with preventative care. Under current models, patients only seek care when acutely sick, meaning systems profit from acute intervention rather than keeping people well. When asked whether the system has any financial incentive to invest in long-term prevention, Eric Topol points out that this flaw is uniquely acute in America: “Well, I would just say welcome to the United States.” Topol emphasizes that other nations with universal models maintain powerful economic and population-health incentives to avoid chronic disease burden. In contrast, the United States relies on fragmented, one-year commercial insurance contracts where payers have virtually no financial incentive to fund disease prevention that will only pay off decades later when the patient is on Medicare or enrolled with a different insurer.

- Even without massive longitudinal datasets, existing models combining EHRs with polygenic risk scores already offer predictive timing for onset rather than generic lifetime probabilities. - Whole-patient clinical models are projected to reach clinical utility ahead of comprehensive virtual cells due to the staggering complexity and diversity of cellular perturbations across the human body. - Single-year commercial insurance coverage in the United States creates a severe structural disincentive against preventative investments, whereas foreign single-payer systems are economically aligned to minimize long-term chronic disease burden.

---

`22:50` The Necessity of Precision vs. Biological Stochasticity

Doug Burger turns to Ava Amini, revisiting the tension between digital hardware design—where precise, deterministic logic abstractions are constructed on top of noisy semiconductor physics—and biological systems. Burger asks whether researchers will ever discover clean, deterministic abstraction layers on top of biology’s stochastic mess. Amini pushes back against the premise itself: “I would like to almost turn the question on its head. Instead of saying, will we get there? Do we need to get there?” She argues that drug discovery and biomedical breakthroughs do not require atom-by-atom interpretability of every moving molecule or deterministic tracking of cellular responses. Instead, the priority must be engineering coordinated orchestrations of models capable of generating actionable hypotheses that bench scientists can experimentally validate within one to two years.

Eric Horvitz supports Amini's perspective, emphasizing that systems engineers must recognize the fundamental difference between silicon architecture and biology: “There's a huge headroom, Doug, between what you asked for when it came to the precision of a systems architect and a hardware architect and what we can do to deliver incredible, incredible benefits to patients under, under some uncertainty under stochasticity with, with, much deeper knowledge about causation across the levels of understanding in human physiology.” Burger takes the critique in stride, joking that both researchers are politely telling him that his thirty years as a hardware architect have biased his worldview and that he should stop trying to force computer architecture paradigms onto living organisms.

- Modern drug discovery and experimental biology require predictive outputs that can be validated in wet labs over one- to two-year horizons rather than complete, fine-grained mechanistic interpretability. - Inherent thermodynamic entropy and biological dynamism make full deterministic modeling unlikely, but clinical utility does not require hardware-grade determinism. - Understanding multi-scale physiological causation under uncertainty offers enormous headroom for life-saving interventions without reaching absolute molecular precision.

---

`25:40` Clinical Frontlines: Ambient Scribes, Diagnostic Errors, and Artificial Empathy

The conversation turns to how real clinicians and patients interact with artificial intelligence on the ground. While an entrepreneurial explosion is generating thousands of health tech startups, the broader healthcare infrastructure remains notoriously slow-moving due to its immense regulatory footprint and share of the gross domestic product. Eric Topol highlights three distinct waves of AI integration currently transforming care:

```mermaid flowchart LR accTitle: Three Waves of Clinical AI Integration accDescr: Flowchart showing the operational, diagnostic, and patient-relationship impacts of AI in healthcare.

subgraph Wave1["1. Administrative Relief"] A["Ambient Scribes"] --> B["Automate Charting & Orders"] B --> C["Reduce Data Clerk Burden"] end

subgraph Wave2["2. Clinical Accuracy"] C --> D["Diagnostic Oversight"] D --> E["Mitigate 800,000 Annual Errors"] end

subgraph Wave3["3. Restoring Care"] E --> F["Patient Access & Empathy"] F --> G["Reclaiming the Doctor-Patient Bond"] end ```

The first wave is operational: ambient clinical scribes that capture doctor-patient conversations and generate clinical notes. These ambient tools eliminate massive amounts of administrative keyboard time for physicians, while producing documentation that is cleaner and more accurate than traditional medical charts. These systems can autonomously draft lab orders, schedule follow-ups, and generate patient reminders.

The second wave directly tackles diagnostic accuracy. Topol underscores that diagnostic error represents a silent public health crisis, citing research that underscores the human stakes: “That is, our diagnostic accuracy, he referred to treatment accuracy, but our diagnostic accuracy is horrible, and they wind up with all sorts of disability and deaths estimated by Johns Hopkins at 800,000 a year.”

The third wave is consumer-facing and involves an unexpected dynamic: artificial empathy. Because overloaded clinicians are forced to rush through appointments, patients are turning to conversational LLMs to review lab results and ask follow-up questions. Surprisingly, patients frequently rate these tools as far more compassionate, patient, and responsive than their human caregivers. Topol candidly admits his initial surprise: “Now, I would never have predicted that because a machine wouldn't know empathy if it fell on it. But it turns out it can channel it.” Rather than replacing physicians, Topol hopes this efficiency will grant doctors the "gift of time," reversing decades of erosion in the sacred doctor-patient relationship. Burger resonates with this loss, noting that while he can still vividly remember the name of his childhood family doctor, he cannot name his last five physicians. Burger then begins to frame how this rapid transformation mirrors—and potentially eclipses—the historic exponential trajectories of computing and Moore's Law.

- Ambient clinical scribes are rapidly being adopted throughout the US to relieve clinicians of excessive electronic medical record documentation, improving note accuracy and handling downstream orders and follow-ups. - Diagnostic errors contribute to an estimated 800,000 deaths and serious permanent disabilities annually in the United States, representing a primary target for diagnostic AI assistance. - Chatbots are increasingly sought out by patients for unhurried, empathetic reviews of lab results, compensating for the severe time constraints imposed on modern clinicians. - The overarching goal of clinical AI adoption is to automate data entry and administrative overhead to restore meaningful doctor-patient face time.

`30:00` Plummeting Token Costs, the Analog Bottleneck, and AI-Guided Experimentation

Doug Burger kicks off the discussion by highlighting an astonishing trend in computing economics: the cost of serving tokens on a fixed-size model has been plummeting by roughly 4x to 10x per year. While explosive model growth often masks these savings, Burger wonders what this means for whole-patient models, virtual cells, and the broader healthcare system. Will these computational cost curves drive down the cost of medical care and drug discovery, or will advanced personalized medicine become so complex that it turns into an unaffordable luxury accessible only to a select few?

Ava Amini responds that on both the biosciences and drug discovery discovery fronts, the real promise lies in trading computation for physical experimentation. By using in silico queries to model causal interventions—predicting how an output state changes based on an input intervention—researchers can prioritize high-confidence regions of the vast search space. This lets laboratories drastically reduce physical spend on reagents, personnel, and money while shortening development timelines:

> “And as the cost of tokens goes down, the hope is that that acceleration will amplify because now the computational side is the faster iteration side of this whole discovery loop versus the experimental one.”

Burger pushes back, predicting that over the next five years, token costs for running such experiments could fall by another 1,000x to 10,000x. He questions whether this extreme disparity simply makes the analog, physical world the inescapable bottleneck. Amini acknowledges the constraint directly:

> “I think the fact is the real world will always be the bottleneck, right? You cannot replace the real world entirely by virtual experimentation, will always need the real world.”

Rather than replacing wet-lab science, she explains, computational models will direct experimentalists to allocate real-world effort to areas backed by rigorous computation. Doug Burger wryly observes: “I think it's a very strange world we live in where the real world will always be the bottleneck, is a quote that we all just heard and probably agree with.”

Eric Horvitz builds on this idea, describing his excitement for models that compute where the greatest informational value lies based on expected probability distributions. Rather than running blind trials, AI can perform active learning to pinpoint where the most surprising or impactful findings will occur. Burger compares this targeting mechanism to “beam forming to save lives,” which Horvitz confirms: “Guiding experimentation, in other words, and faster computing and cheaper tokens will help us do that better, which basically addresses directly the bottleneck.”

```mermaid flowchart LR accTitle: Trade-off between In Silico and Wet-Lab Workflows accDescr: Computational simulations prioritize high-confidence candidates to guide expensive physical wet-lab experiments.

subgraph InSilico["In Silico (Computational Loop)"] A["Low-Cost Tokens & Models"] --> B["Causal Intervention Queries"] B --> C["Value-of-Information Beam Forming"] end

subgraph Physical["Physical Lab (Analog World)"] D["Prioritized High-Confidence Tests"] --> E["Wet-Lab Verification Reagents & Cells"] end

C -->|"guides experimental spend"| D E -.->|"ground truth data feedback"| A ```

---

`34:58` The Data Bottleneck and the Shift from Labeling to Supercomputing

Eric Topol shifts the conversation from computing power to what he sees as the true limiting factor: datasets. While billions of dollars are being poured into life science data, longitudinal, deep multimodal patient records are nearly nonexistent. While standard electronic health records exist, they lack the rich, layered biological depth required for true modeling. Topol points out that the field's hallmark success story relied on a unique historical asset:

> “I mean, so, you know, remember, Eric pointed out early on that AlphaFold has been the signature contribution. And that was because we had the Protein Data Bank. The data set was all there. All it took was, you know, milking it for what it could do with AI. Now, we don't have any data set like that in life science or in medicine.”

Burger draws an analogy to computer science in the 2010s. His engineering teams built inference-serving platforms for Recurrent Neural Networks (RNNs), where progress was severely bottlenecked by the need for scarce labeled data. That constraint vanished with the advent of the Transformer architecture, which unlocked self-supervised training on massive corpora of unlabelled text and instantly shifted the challenge from a data problem into a pure supercomputing challenge. Burger asks whether the biosciences could experience a similar architectural inflection point that renders current data shortages obsolete.

- **Token cost deflation:** Serving tokens on fixed-size models has dropped 4x–10x annually, with expectations of a 1,000x–10,000x drop over five years. - **The AlphaFold precedent:** AlphaFold succeeded because decades of experimental crystallography were consolidated in the open-access Protein Data Bank (PDB). - **The 2010s paradigm shift:** Machine learning transitioned from hand-labeled supervised RNN pipelines to self-supervised Transformer models scaled purely by compute clusters.

---

`37:32` The Wish List: Dynamic Activity-First Biological Datasets

Eric Horvitz reflects on Burger's historical comparison, noting that opportunistic utilization of genomic libraries and nucleic acid sequence collections is already yielding novel predictive models without relying strictly on protein structural templates. Horvitz then poses an "Aladdin's lamp" thought experiment to Ava Amini: if she possessed a magic wand and could summon three massive biological or clinical databases linking phenotypes to molecular sequences, what would she ask for?

Amini points out that while the Protein Data Bank was pivotal for AlphaFold, it suffers from a fundamental limitation: it captures static, frozen structures. Biological entities, by contrast, depend on dynamic, time-dependent movement to carry out their functions:

> “It is limited because these are static structures of proteins and we know that proteins are dynamic and they're active, right? They execute function through activity. And so I think the real missing thing is these kind of activity first datasets for different layers of the biological stack.”

Amini argues that biology desperately needs scaled datasets mapping protein sequence directly to activity across diverse functional profiles, replacing the isolated, small-scale datasets scattered across historical literature. She stresses that this need is even more acute at the cellular level. Because the human body contains a vast array of specialized cell types, it is impossible to brute-force test every single cell against every possible chemical perturbation. Instead, progress will depend on designing principled, activity-first datasets that allow models to systematically generalize across both cellular behavior and expansive chemical search spaces.

`40:00` Functional Readouts and the Missing Layer of the Immunome

Ava Amini emphasizes that a critical blind spot in modern computational biology is how researchers decide which parts of biological space to sample to build diverse datasets. In particular, she points out the acute shortage of functional readouts across molecular, cellular, and tissue scales. Describing ongoing work, she explains:

> “And in our ex vivo collaboration, we're tackling part of this in the context of cancer cell development, cancer cell measurements, looking at trying to build what we call state to function maps that look at a spectrum of cancer cell states and measure functional outcomes.”

These maps track functional behaviors such as resistance to immunotherapies or targeted treatments. While bridging cell states to clinical outcomes is only one slice of the problem, Amini insists that prioritizing functional biological readouts over static snapshots is essential.

```mermaid flowchart TD accTitle: Mapping Biological State to Functional Outcome accDescr: Flowchart showing cell state measurements translated to functional biological readouts and therapeutic response. subgraph S1["Cellular Profiling"] A["Cancer Cell Spectrum"] --> B["Cell State Signatures"] end subgraph S2["State-to-Function Mapping"] B --> C["State-to-Function Maps"] end subgraph S3["Clinical Readouts"] C --> D["Immunotherapy Resistance"] C --> E["Targeted Therapy Resistance"] end ```

Doug Burger turns the floor over to Eric Topol to start an "around the horn" series of insights on the most exciting current developments before pushing the discussion into more radical territory. Topol immediately highlights the immune system as the fundamental missing link in human health profiling:

> “Well, you know, I think the missing layer in humans is the immune system, the immunome. And everything we've learned to date points to that as a critical underpinning of the healthspan.”

Topol shares that his group published a paper in *Nature* that very day detailing the immunome. Modern AI capabilities are reshaping long-held immunological dogmas. For example, while textbooks previously taught that the thymus gland involutes into an inert structure by age 20, new imaging and analytical tools show that some 80-year-olds retain a fully intact, functioning thymus. This structural preservation correlates with cancer susceptibility and immunotherapy efficacy. Coupled with immune-cell proteomic clocks that track biological versus chronological age, deep immune profiling can finally move beyond tiny academic cohorts of 20 patients into scalable, granular models that clarify mechanisms in cancer, neurodegeneration, and atherosclerosis.

- **Nature publication**: Eric Topol's team published an analysis of the human immunome on the day of the recording. - **Thymus gland dynamics**: Historically assumed to become non-functional after age 20, intact thymuses are now observable in healthy 80-year-olds via advanced AI-assisted imaging. - **Proteomic immune clocks**: Tracking divergence between immune age and chronological age clarifies vulnerability to cardiovascular diseases, brain degeneration, and malignancies.

---

`43:20` Foundations of Aging and the Mystery of Late Penetrance

Eric Horvitz zooms out to address the systemic biology of aging, arguing that investigating foundational aging mechanisms will yield far higher dividends than studying isolated diseases. He raises the fundamental puzzle of disease penetrance: why do specific genetic liabilities remain silent for decades before causing overt clinical damage?

> “Even genetic lesions like LRRK2, something called LRRK2 transposition for Parkinson's disease, it shows up in the 60s and 70s. But why? Why did the body hold off until then?”

Horvitz points out that the same delayed onset governs Alzheimer’s disease and most neurodegenerative disorders. He draws an analogy to computer hardware, describing epigenetic gene expression marks as microscopic DIP switches turning cellular programs on and off to maintain differentiated cell types. Over time, that coherence decays into biological noise, entropy, and chaos. Uncovering the causal mechanisms behind why those switches falter—and developing interventions to stabilize them—could resolve entire classes of age-related illnesses simultaneously.

The discussion prompts a warm, humorous exchange: Burger quips about the inevitability of physical entropy, while Horvitz notes Topol’s dedicated work on super-agers, apologizing jokingly for wandering onto Topol's academic turf.

---

`45:00` Creative Computation, Multiscale Measurement, and Systems-Level Phenotypes

Asked what excites her most, Ava Amini splits her perspective into technical and biological horizons:

> “On the technical side, coming back to our data discussion, I think innovations that allow for creative utilization of existing data such that we can turn it into a supercomputing problem, as you pointed out, Doug, is something of great interest and excitement for us here and in general in the field.”

Amini argues that while certain critical measurements are still missing, massive reserves of biological data already exist. Developing algorithms that creatively reframe this dormant data into massive compute challenges allows researchers to exploit supercomputing infrastructure fully.

On the biological side, Amini champions novel measurement technologies that bridge distinct layers of the biological hierarchy. Rather than fixating on the current industry hype around building isolated "virtual cells," she urges the field to focus on higher-order, systems-level readouts—such as whole-organism aging and systemic immune behavior—where multiscale inputs genuinely determine patient phenotypes.

---

`47:30` DNA as Software and the Realization of Synthetic Biology

Doug Burger pushes the conversation into speculative territory, questioning whether humanity will ever reach the point of fully compiling complex organisms from scratch. DNA indirectly specifies the self-assembly of specialized tissues, neural networks, and whole organ systems through emergent rules. Burger wonders aloud whether bioengineers might eventually author genetic programs that generate arbitrary, macro-scale multicellular systems—such as an engineered cellular mass designed to extract carbon dioxide from the atmosphere and secrete marine algae.

Amini responds that this ambition lies at the very core of synthetic biology:

> “Yeah, I think that programmability is kind of the promise, right? Can we do functional design and engineering of biology through interfaces that make sense to us as humans, whether that's natural language, whether that's other modalities, even perhaps images...”

Recalling her undergraduate engineering days, Amini reveals that her entry point into the discipline was constructing finite-state machines inside *Escherichia coli*. By designing synthetic genetic circuits capable of executing logical state transitions in response to specific combinations and sequences of chemical inputs, her team treated cells as living computational engines.

```mermaid flowchart LR accTitle: Paradigm Evolution of Biological Programmability accDescr: Timeline comparing undergraduate genetic logic circuits with modern AI-driven functional protein design. subgraph Early["Early Synthetic Biology"] A["Chemical Inputs"] --> B["Genetic State Machines in E. coli"] B --> C["Engineered Logic Output"] end subgraph Modern["Modern Generative AI"] D["Natural Language / Image Prompts"] --> E["AI Generative Models"] E --> F["100+ Functional Candidate Proteins"] end ```

The paradigm has rapidly evolved from primitive gene circuits into multimodal generative foundation models capable of parsing natural language functional prompts and automatically spitting out 100 de novo protein candidates engineered to execute that exact function. Horvitz adds an illustrative example of this engineering mindset: integrating miniature digital counter circuits into human lineages to record cell replication cycles, allowing a clinician to read out directly whether a cell has divided four times or a thousand times to flag malignant proliferation.

- **Synthetic state machines**: Programming DNA sequences to act like logic gates and register sequential chemical states inside bacterial chassis. - **Generation counting circuits**: Theoretical genetic circuits designed to measure division milestones to detect senescence or early oncogenesis. - **Multimodal functional prompts**: Specifying desired biochemical properties via text or visual interfaces to generate targeted molecular structures.

---

`50:48` Real-Time Genome Editing and Ten-Year Healthcare Predictions

Burger jokingly teases Horvitz and Amini, remarking that by arguing for such rigorous, programmable genetic circuits, they are slipping back into biological determinism despite their earlier warnings about biological stochasticity. Topol laughs in agreement and affirms that the timeline toward programmable biology is compressing dramatically:

> “The things that we're seeing recently, you know, like Jay Shendure up at UW with being able to do genome editing during embryogenesis in real time. These are things that were inconceivable a year or two ago, maybe even a month ago.”

Topol notes that while concepts of engineered organisms designed to clean up environmental catastrophes have existed for years in primitive iterations, modern analytics, generative tools, and editing platforms make functional biological design an inevitable reality—it is purely a question of when.

Wrapping up the episode, Burger invites the panel to share their ultimate takeaways. Amini reflects on why she entered the field: computer science offers an unmatched conceptual tool set and abstraction system for deciphering and redesigning biology to help patients and the planet.

Horvitz offers a concrete prediction for the next decade of clinical medicine:

> “Ten years from now, the average person, the public, will recognize AI as having led to impressive breakthroughs in healthcare. And this will include transforming a number of fatal cancers into chronic diseases by then and making a headway into delaying onset and progression of Alzheimer's disease, among other breakthroughs.”

`55:00` Radical Optimism and Closing Reflections on the Future of Medicine

Looking beyond near-term milestones, Eric Topol expresses profound optimism about the transformative reach AI will have on human health in the coming decades. He argues that the true measure of success will not merely be incremental treatment enhancements, but the fundamental capability to stop debilitating conditions before they take root. Pointing toward diseases that currently lack effective preventive solutions, he envisions a systemic shift toward proactive interventions. As Topol puts it: “Yeah, my optimism extends even beyond that, that we will have the ability to prevent Alzheimer's disease and prevent cancers that we aren't today.” Despite the institutional and technical friction points discussed throughout the conversation that continue to hold adoption back, he projects that the discipline is heading toward an inevitable, comprehensive reimagining: “But we eventually will have a medicine of practice that is unrecognizable from today.”

Doug Burger brings the episode to a close by expressing deep gratitude to the panel—Eric Topol, Eric Horvitz, and Ava Amini—for sharing their insights. Acknowledging the heavy demands placed on researchers and clinician-scientists who operate directly on the frontier of AI and healthcare, Burger notes that every hour committed to such dialogues is a deliberate pause in their ongoing work, observing that “time spent away from their research is time spent away from inventing the future.” Calling the exchange a genuine privilege, he bids farewell as the guests exchange closing thanks to wrap up the discussion.

- **Key preventive frontiers:** AI-driven medicine aims to unlock the ability to prevent conditions such as Alzheimer's disease and various cancers that modern healthcare currently cannot avert. - **Pace of adoption:** While structural bottlenecks remain, the long-term trajectory points toward a medical practice that will look completely unrecognizable compared to contemporary standards.

## Notable quotes > `50:48` Ten years from now, the average person, the public, will recognize AI as having led to impressive breakthroughs in healthcare. — Eric Horvitz

> `40:00` I think the missing layer in humans is the immune system, the immunome. And everything we've learned to date points to that as a critical underpinning of the healthspan. — Eric Topol

## Mentioned Doug Burger, Eric Horvitz, Eric Topol, Ava Amini, Jay Shendure, Microsoft, Microsoft Research, Scripps Research, Broad Institute, Project Ex Vivo, Science, Nature, Johns Hopkins, AlphaFold, Protein Data Bank, The Shape of Things to Come

## Video description <p>What can AI enable in medicine, and how do we get there? Microsoft Research lead Doug Burger, Microsoft Principal Research Manager Ava Amini, Microsoft Chief Scientific Officer Eric Horvitz, and physician-scientist Eric Topol of Scripps Research explore these questions and more.</p><p><a href="https://www.microsoft.com/en-us/research/podcast/can-ai-help-deliver-the-health-breakthroughs-we-need/">Show notes</a></p><p><a href="https://www.microsoft.com/en-us/research/story/the-shape-of-things-to-come/">The Shape of Things to Come podcast series</a></p>

[Source](https://media.blubrry.com/microsoftresearch/content.blubrry.com/microsoftresearch/MRP-2026-11-30-332.mp3)

Reading summary

Researchers Eric Horvitz, Eric Topol, and Ava Amini argue that while artificial intelligence is shifting from static diagnostic scoring to dynamic medical cognition and biological engineering, realizing its clinical potential requires navigating complex biological multiscale hierarchies and overcoming deep structural inertia in healthcare systems. Agentic Medical Cognition and Frontline Practice (5:00) Diagnostic AI evaluation is moving away from grading complete, static clinical vignettes toward modeling sequential medical cognition. Horvitz describes a Science cover study by Microsoft where an AI agent adopted the posture of an ambulatory clinician—deducing which questions to ask, balancing the diagnostic value of tests against financial and procedural costs, and knowing when to stop testing. Topol notes this agentic model nearly doubled the diagnostic accuracy of generalist physicians while lowering overall testing costs, running counter to existing healthcare AI deployments that primarily focus on billing optimization. At the clinical frontline, Topol outlines three distinct waves of AI integration: operational ambient clinical scribes that automate charting and orders, diagnostic safety tools designed to mitigate an estimated 800,000 annual US deaths and permanent disabilities caused by diagnostic errors, and consumer-facing conversational models. Overloaded human caregivers often lack time, leading patients to consult chatbots that provide patient, empathetic explanations of laboratory results. Structural Disincentives and the Implementation Gap (10:00) A substantial implementation gap separates peer-reviewed AI breakthroughs from routine patient care. Despite validated real-world evidence—including 44 randomized controlled trials in colonoscopy and screening studies encompassing more than 100,000 women in mammography—practical adoption remains negligible. Topol points out that almost no American women receive state-of-the-art AI interpretation for mammograms without paying out of pocket, attributing this inertia to narrow hospital operating margins and an absence of clinician and public demand. This deployment failure is reinforced by healthcare economics. In the United States, fragmented one-year commercial insurance contracts disincentivize payers from funding preventative AI interventions whose health and cost dividends will only materialize decades later. In contrast, Topol observes that universal single-payer healthcare systems maintain direct economic alignment to fund preventive interventions that lower long-term chronic disease burdens. Multiscale Modeling and the Experimental Bottleneck (12:12) Applying AI to biological discovery introduces distinct computational hurdles because living organisms operate as multiscale dynamical systems spanning molecules, cells, tissues, organs, and the whole body. Addressing whether biology requires clean, deterministic abstractions like computer hardware, Amini and Horvitz argue that clinical breakthroughs do not require atom-by-atom interpretability. Instead, models need to untangle causal mechanisms and produce actionable hypotheses that bench scientists can experimentally validate within one- to two-year timelines. Furthermore, while serving tokens on fixed-size models has dropped in cost by 4x to 10x annually, computational acceleration cannot entirely bypass physical biology. As Amini and Burger note, in silico simulations allow active learning algorithms to beam-form and prioritize the most informative hypotheses, but physical wet labs evaluating real cells and chemical reagents remain the ultimate analog bottleneck. Dynamic Datasets and Systems-Level Health (37:32) Progress in biological AI is currently constrained by an acute shortage of dynamic datasets. While AlphaFold capitalized on decades of static crystallographic data preserved in the Protein Data Bank, Amini highlights the necessity of new activity-first datasets that map dynamic protein sequences and cellular states to functional behaviors, such as therapy resistance. Rather than focusing exclusively on single-cell simulations, she urges researchers to capture systems-level phenotypes. Topol identifies the immune system as a vital missing layer in whole-patient modeling, referencing recent findings that reveal functional thymus glands in certain 80-year-olds and utilizing proteomic clocks to measure biological age versus chronological age. Similarly, Horvitz emphasizes that uncovering foundational aging biology—such as the epigenetic decay and loss of cellular regulation that causes genetic mutations like LRRK2 in Parkinson's to delay clinical penetrance for decades—could address entire families of age-related diseases simultaneously. Horvitz forecasts that over the next decade, AI breakthroughs will transform several fatal cancers into manageable chronic conditions and delay the onset and progression of Alzheimer's disease, while Topol predicts medicine will ultimately transition from reactive treatment to proactive disease prevention. However, both milestones depend on whether the scientific and healthcare communities can successfully bridge the gap between in silico modeling, wet-lab validation, and institutional clinical adoption.

Source quotes

[50:48] Eric Horvitz: Ten years from now, the average person, the public, will recognize AI as having led to impressive breakthroughs in healthcare. [40:00] Eric Topol: I think the missing layer in humans is the immune system, the immunome. And everything we've learned to date points to that as a critical underpinning of the healthspan.

Original transcript

[0:00] This is The Shape of Things to Come, a Microsoft Research podcast. I'm your host, Doug Berger. In this series, we're going to venture to the bleeding edge of AI capabilities, dig down into the fundamentals, really try to understand them, and think about how these capabilities are going to change the world, for better and worse. Today, I'm bringing three experts in the fields of biomedicine, of AI, biology, and medicine to see where healthcare is going, where the deep understanding of biology is going, what medical advances are coming, and how will AI change the future of health? These questions are really important because they will determine the shape of things to come. In today's podcast, I've invited three leading researchers in medicine, biology, and machine learning slash AI. Eric Horvitz is Microsoft's chief scientist and is both a PhD and an MD. How you spend all those years in school, I have no idea. I've known Eric for decades and his work has shaped the entire field of machine learning. He's a legend in the machine learning community and is a good friend. Eric Topol is our second guest. He's the executive vice president of Scripps Research, the largest nonprofit biomedical research institute in the United States. He's published over 1,300 peer-reviewed papers. Shocking, shockingly productive. Authored four books. So just an amazingly impressive book. a prolific scientist and physician. Finally, Ava Amini is a principal research manager in Microsoft Research. She's a rising star in our organization, an expert in the intersection of AI and precision medicine, and she's a co-lead of Project Ex Vivo, a collaborative effort between Microsoft and the Broad Institute that is focusing on defining, engineering, and targeting cell states in cancer. So thank you all for joining today. I think we've got a really, really amazing set of people, myself excluded. And I'd like to start to my guests here. It's clear there's a huge disruption happening at the intersection of biology and medicine and AI right now. Just, you know, we're seeing things, breakthroughs happening at an accelerating pace. Models are helping us to discover structures and create extractions that are really useful for moving forward the field of medicine. I've seen some recent talks where scientists with cancer used AI to design drugs for themselves, which, I mean, just unbelievable. And today I've got some long term questions for us to discuss, maybe a little bit provocative, but I'd like to start with what each of you see. as what's happening right now like on the on the intersection of medicine and biology and ai i think each of you has a unique vantage point i'll go around the horn and i know eric there's a uh you know you have a cover article on science magazine that's really exciting and so maybe you could talk a little bit about that as well so i'll start with you And then I'll go to Eric Topol and then Ava. Thanks, Doug. I think health care and the biosciences are fortunate disciplines in that there's been a digitalization of content. whether it be protein structure over decades, electronic health records, and so on that makes these fields amenable to – being at the ready for AI inferences and innovation. And therefore, I've been extremely optimistic about the long-term development futures as well as what we'll see early on at the frontiers of AI when it comes to the biosciences and health care. Just extraordinary to see what's happened over just the last five to eight years in the biosciences with both discriminative and generative AI models. you know, the, AlphaFold's breakthrough was tip of the iceberg, and we see just a whole, in some ways, a crest and a crashing of a wave of possibilities now when it comes to experimental platforms, experimental design, data interpretation in the biosciences, hypothesis generation, I should say, as an assistant and a companion to scientific reasoners and human scientists. who we have a starting opportunity to address. [5:00] long-term challenges in patient safety and in getting to timely diagnoses and accessibility of health care. And after a couple of years of intensive work, I and just fabulous colleagues at Microsoft worked intensively on taking health care challenges when it comes to applications of of AI and benchmarking medical diagnostic challenges, for example, and moved it into what I would call the realm of medical cognition, where instead of looking at a whole case that's given to an AI system and looking at the accuracies that are reported on its ability to diagnose, for example, a form of differential diagnosis, we instead put the AI system in the shoes of a clinician. a little window on what's going on when a patient comes in in an ambulatory setting. And then it's up to the clinician to ask the right questions and to then think about tests, balancing the information value with the cost of the tests. This is the sequential diagnosis challenge. And we applied AI to both the formulating hypotheses component of that, as well as decision-making about the next best tests to order, questions to ask, and also went to call a diagnosis, as a concluding convergent diagnosis and getting on with things with therapy, for example. And so just, I think, remarkable abilities of... a number of of of frontier language models to do a fabulous job and you know and again did some comparisons with with human generalist physicians uh which have to be taken at face value with limitations in what we did with on the comparison but still show the promise of the methods for assisting clinicians of the future Well, congratulations on the paper. It's a really big deal. So Eric, moving on to you, you're the one person on the podcast who's not a Microsoft employee. And so you see a very different, I think, set of things than we might see from our vantage point, although I think each of the three of us sees different things in general. Could you just tell us what you're seeing? Like to somebody listening, you know, we have a broad listenership from all different segments, not just experts in AI or medicine. Like, what are you seeing that your sort of technical, smart, average listener is? would be able to take away? Yeah, sure, Doug. I mean, I think first, I do also want to congratulate Eric and the team at Microsoft, because this was a seminal paper in science. It was the first ever to take an agentic system and make more accurate diagnoses, not just compared with physicians, but a lot of the other frontier models, markedly improved accuracy over positions, almost doubling, but at lower cost. I mean, that's something we haven't seen. What we've seen is using AI to upcode and using AI to potentially raise costs. This really was the first demonstration you could have higher accuracy at lower cost. It's kind of like eat more, weigh less, or it tastes better. Anyway, it's pretty impressive work. is that we have all attuned to the shiny object of generative AI. which is great, it's, you know, four years in, but we somehow missed using where it's even more proven, which is in the image phase of deep learning of medical images, whether it be the retina, chest X-ray, electric cardiogram, all these things. And so there's this real paradox where, for example, we aren't implementing all that we've learned from mammography. Over 100,000 women in a randomized trial or colonoscopy, 44 randomized trials and eking out all the embedded information that humans can't see. But AI can interpret from every type of medical image that we know of. So we're not harvesting that opportunity. Now, why is that important? Well, the next phase of AI is, you know, I guess what I'd call whole patient models. whereby we would have, as Eric mentioned, electronic health records, we'd have all the images, raw images. and other layers of data. It could be genomics, it could be proteomics, it could be, you know, the exposome, all these layers of data. But we can only get the most out of that at the individual level for being able to predict diseases, and when they might have come [10:00] and what-if scenarios if we change something to defer or prevent the disease, and using these sorts of remarkable data sets to really change medical care in a way we've never done before. So I'm excited about that, but we are still idling. We haven't used the work that's been done to affect patient care. I'm still waiting for that to happen, Vetson, to say the least. Just before I go on to Ava, you know, since you raised that, and what do you think the community should do differently so that we're not missing that opportunity? I mean, there's a ton of research going on. There's a lot of work. There's businesses adopting AI. What is the community missing? Well, it's missing implementation. So it all sits in these great journals and, you know, gone through peer review and just impressive data, particularly these randomized trials that were done in the real world and not used in caring for patients or helping patients. So there's no real good reasons why this hasn moved forward There lots of excuses But the medical profession is slow to adopt change Oftentimes, there's financial constraints, there's unwillingness to invest at health systems level, because they're working at very low margins. And they don't want to get into something that they're not fully confident with. You know, one thing that's noteworthy is the physicians are not clamoring for these advances. I mean, if I or the patients, if you're a woman undergoing mammography and you don't get state of the art AI, which almost, you know, no women in the United States do, you think you might run a revolt or you have to pay for it to get that interpretation and a very limited network. There's so many of these things that people are not getting that either the physicians who advocate for patients or the patients themselves, maybe that's what we need to drive this forward. I'm going to come back to that. That's a really, I think, important point because it touches on just the economics of the system But Ava let me turn to you You deep in it right You playing with the models and working with outside organizations and actually pushing on disease states So what are you seeing right now? Yeah, from where I sit specifically, it's at the intersection of AI and biology. So more focused on the biosciences versus medical and healthcare, but the perspective is very complementary to what Eric and Eric were both mentioning, because right now we're at this phase of extreme excitement, a lot of optimism, a lot of energy, a lot of investment. But when it comes down to it, the reality is implementation again, where we have enthusiasm about building predictive and generative models, AI models for biology. But really the question in my mind is, what are these actually going to solve? What questions can we deploy them towards? How are we going to implement them? How will they be adopted by experimental scientists and integrated into our workflows? And that is a gap that I think still the community needs to bridge. We're making steps towards bridging that For example through our collaboration with the Broad Institute where we really trying to build bottom up a joint research endeavor that marries both the AI side and the biological side And so in the next phase, I think really the challenge and the test will be how can we implement these models and systems in a meaningful way towards meaningful problems. And then the second big piece that I'm seeing and I'm really strong on is very aligned with this vision of the whole patient model. And it comes down to the fact that biology is incredibly complex because it's inherently multiscale, right? We have operation at the level of molecules that then go on to the level of individual cells that organize into tissues and organ systems. And those organ systems all function within an organism in a remarkably coherent way. And that's a machine learning and computational challenge that is very hard to find in any other field. field, how you actually integrate across these scales of a hierarchy in a coherent way such that context and information from all the way down at the molecular level can be brought up meaningfully to insights at the patient level or the human level. [15:00] And so because of these complexities, there's so much opportunity as well for real AI innovation in terms of how we bring data to these models, how we represent the data, what type of data we need, how much of it, how diverse should it be, all these very fundamental technical questions. is the number one or number two or number three highest set of priorities that we would deploy such a system for? Or do we democratize and go after a breadth rather than a depth of applications? So really, it's a tremendously exciting time for research on both the computational side and biology side for these reasons. I... We keep coming back to the whole patient model, so I want to toss out maybe a provocative question, and I'll use my platform to – draw back to my old historical area, you know, so I'm, I think, as you all know, I'm a computer architect by training, so build systems out of chips and software and wires, and, you know, One of the things in that part of the field in computing is that we humans have built these incredibly complex systems, like literally billions of circuits on a posted-sized stamp chip. But we understand... pretty much everything about them because we've, We've built them from the ground up. We've created the abstractions, we've created the rules of going from one layer to the other. But of course, deep inside the transistor junctions, it's a messy stochastic dance, quantum dance of electrostatic forces and the PN junctions are really stochastic devices. but we just build these abstractions that are clean. Do you all ever think we'll get to a point where biology is the same way? Like we understand it well enough, we have a hierarchy of abstractions, and we know what everything does. And we can point to any part of the system and say that's it. Or is it always going to be this messy thing that's just so complex we can't possibly understand it? Thank you. once we run a deep generative model on that very clear, precise set of abstractions that you've provided in your career. We're back into messiness again and really trying to understand the algorithmic behavior, especially when it's stochastic. My sense is carrying the analogy forward to a multi-scale dynamical system, the human body, is that there's going to be very high degrees of... complexity when it comes to the dynamics and interactions of parts at different levels of abstraction. And thus, we'll have to think through... What? are ways to manage that complexity in our inferences and in our tests and in our studies and in our data collection, such that we could... again, keeping moving the analogy forward to the, Come up with it. techniques for interpretability of what we see and what we can intervene as well as causal models and abstractions that help us understand both intra-level and cross-level interactions. I think that was a no. Well, you know, it was a no that we will never understand, you know, the details, the critically important details down to the precise atomic level of the kind that you had and have had in architectures and systems design. So, yes, I could have been right, but I could have just said no. No, no, no. I'm just trying to simplify it for the audience. Sorry. Sorry, I went on a long discourse. I did a low-rank approximation on Eric Horvitz and got one. Sorry to boil you down. It's helpful. Any other comments here? Yeah, I'm going to disagree. A couple here. Firstly, as you know, there's a lot of interest in creating the virtual cell. Yeah. Where you would be able to do any number of perturbations and predict its response, unravel a lot of biology. Now at the patient human, the virtual human level, we are so weak right now. The virtual cells a ways off, but the virtual patient kind of analogy, like for example, If you had a polygenic risk score, or even a genome sequence. You might say, "Oh, this person has risk for, say, heart disease, but we don't know whether [20:00] It's age 50 or 90. You know, that's not really that helpful. So what it turns out is when you even the models that have been done so far and published, they already can give us some timing. They can already color this. And we are still looking for deep. That's just with electronic health record and lifestyle or electronic health record and polygenic risk score. We don't have deep and long data yet at scale. Wait till we get that. So I do think we're actually going to get to some more mature whole patient models before we get to the virtual cell. We're never going to get to be able to do all the perturbations you could do at a cell level but there's a lot of different cells in the body yeah but one other point about this is that we really need to be beyond you're at risk for. We have a real chance to enable prevention. We've never really done in any meaningful way in health care. So I think it's an exciting step forward, but it's going to take a lot of effort to make it real. Thank you. I was at a conference this past weekend on the intersection of AI and medicine, and that topic, Eric, came up, prevention. And I think the argument that some very David Morgan: Thoughtful speakers made is that our economic model of healthcare is just fundamentally at odds with preventative medicine. Like the system isn't incentivized to do it. People can choose to do it. But you know, you go into the doctor when you get sick and the hospital treats you and then you and they might give you some advice. But there's no fundamentally incentive, fundamental incentive. for the system to invest to prevent future problems outside of your maybe your general practitioner. Do you agree with that? Well, I would just say welcome to the United States. That's the model. But if you go elsewhere, you'd find there are incentives to keep the population healthy. Huge economic, no less health burden incentives. So we are in this peculiar, unique environment. situation where we have disincentives because of all the structures that are, you know, one year of insurance coverage. Why would they care to prevent diseases when they have such short-term interests? And, you know, just very poor structurally to make this shift. But it doesn't mean it won't happen. It may just not happen here or only here in select entities like for this sort of shift. Ava, I want to turn to you back to the original question. So digital systems are you know, precise abstractions built on a stochastic mess. Do you think we'll be able to get precise rules about biology on top of all the stochastic messiness, even though it's I would like to almost turn the question on its head. Instead of saying, will we get there? Do we need to get there? I would argue that it's perhaps not necessary to have that complete, you know, Adam Wise or... interpretability of where every molecule in a cell is moving at any given time and how it reacts to this perturbation and so on and so forth. I think it's far more important to think about what are the necessary outputs from a model or a system that's an orchestration of many models, perhaps, to actually enable the discoveries that a scientist is going to. you know, want to undertake. And for me, a lot of things that, you know, are... immediate in terms of being able to, um, look ahead one year, two years down the line to experimentally validate. I don't think we need that level of interpretability. Whether or not we get there is, you know, I think we can... debate about that. I would lean on to the side of Eric H and saying, maybe we, I don't think we will ever precisely get there because of just the inherent entropy and dynamics of biology. But I would take a strong stance of saying, do I think it's necessary? There's a huge headroom, Doug, between what you asked for when it came to the precision of a systems architect and a hardware architect and a hardware architect. what we can do to deliver incredible, incredible benefits to patients under, under some uncertainty under stochasticity with, with, much deeper knowledge about causation across the levels of understanding in human physiology. Exactly. [25:00] you know, what level of that do we need to enable discovery or enable better interventions or treatments or preventative measures, right? You know, I don't think that Fine-grained. precision is strictly necessary for that. I certainly don't think you need to have... that level of understanding to do very, very useful and important things. But I think what the two of you were just doing is very nicely saying, Doug, you're overly biased by your 30 years in your field. Butt out and stop trying to apply your lessons to biology, which I take as a fair point. It doesn't mean I will, but I hear the feedback. So, Eric Topol, over to you for a sec. doctors and just maybe as an initial framing, what I'm also seeing now is an explosion in entrepreneurial activity, people starting companies, people generating new ideas, people Then you have this very slow moving health care system and slow moving just because of the scale at which it operates. Right. It's, you know, a big fraction of the U.S. economy in the United States. So how are you thinking about the role of people and AI? I know it's a loaded question, but you're really more than any of us are on the front lines. It is a tough one to unpack, Doug, because there's so many different dimensions of this. Like, for example, the use of ambient scribes to shorten the amount of data clerk time that doctors and clinicians have, which is starting to really take off throughout the U.S., And those who are frequent users are really, you know, being – rewarded for saving a lot of that keyboard time. Right. Uh, so that's one element, which is kind of operational. Uh, but it turns out once you have a digitized note, it's more accurate than the notes that have been in our charts for decades. Uh, then it does all kinds of things, you know, it does, uh, ordering and scans and lab tests and future appointments and, uh, So it even nudges patients about things that were discussed at a visit or whatever. So that's one phase. The one that Eric mentioned earlier, is starting to be realized, and that is accuracy, promoting accuracy. That is, our diagnostic accuracy, he referred to treatment accuracy, but our diagnostic accuracy is horrible. and they wind up with all sorts of disability and deaths. estimated by Johns Hopkins at 800,000 a year. That's a big toll of diagnostic errors. So I think we're going to start seeing AI help people. And then then we also have this one very peculiar thing that I never would have predicted. And that is because physicians, clinicians are squeezed. They are not having much time with patients. And so patients turn to chatbots and AI to find out that they are more empathetic than humans. Now, I would never have predicted that because a machine wouldn't know empathy if it fell on it. But it turns out it can channel it. And patients like the idea of being able to review lab tests and answer all these questions, have unlimited time, instant access and everything else. So these are some of the movements that are occurring right now on the consumer side, which is big. The alleviation of some of that data clerk function on the part of physicians that are more progressive, that are trying to make the move. And I hope that we'll see a return to the with the gift of time with patients being somewhat more autonomous, physicians having more time with patients that we get back this patient doctor relationship. That's something that's eroded terribly over multiple decades. But we have the signs. that we could actually get that back. And I hope that we will. I could still tell you the name of my family doctor when I was, you know, between five and ten. But I couldn't tell you the names of my last five. So it's a great example. There you go. You know, we talked about the whole patient model. And please, you all bear with me for a sec. In digital computing, we had Moore's Law, which ran somewhere between 50 and 60 years, and I won't bother being all persnickety about what it actually was because there's a popular culture version that's not right. But what it did drive is an annual exponential drop in the price of computing. And what we're seeing now is an even faster [30:00] It... of drop in the cost of tokens. you know, four to 10 X per year. We don't know how long it will go, but it's unbelievable. Now, of course, the models have been growing so rapidly that we don't see those costs. But the cost to serve a token on a fixed size model has been plummeting. And so I wonder when we talk about the whole patient model or virtual cells and all of this data and the cost of the healthcare system, Do you see those trends driving down the cost of medical care and the ability to do these sorts of things? Are there other cost drivers down, or do you think we're heading for a world where it's just going to get more and more and more and more expensive, and, to do all of this advanced stuff for people, and it will be unaffordable except for a few. Yeah, I can start with this one because there is an angle here for both the medical – side as well as the biosciences side in earlier discovery and experimentation and drug discovery workflows. And there I would say the promise is this idea of trading off computation for experimentation and having an interplay between the two where some of the experimental cycles that you do spend in the lab are those that are high confidence, you know, areas of that experimental search space that are prioritized by a model, let's say, such that you can use experimental resources much more efficiently, whether that's money reagents, physical reagents, personnel, and therefore drive the cost and the lead time to discoveries down by doing some experiments virtually, if you will. So running, um, queries in Silico that can then... project the outcome of an experiment in a causal way, given an input state, what is the output state of following this intervention, right? Therefore, you can basically, balance the cost expenditure in this way such that you can really, really drill down in the real world on those... things that are most promising, hopefully with faster timelines and lower overall, you know, experimental spend in the lab. So that is could be one way that And as the cost of tokens goes down, the hope is that that acceleration will amplify because now the computational side is is. the faster iteration side of this whole discovery loop versus the experimental one. But before we go to the Eric's on that question, over the next five years, I would guess the cost of tokens for running these experiments will drop somewhere between 1,000 and 10,000 X. So doesn't that make the analog, the real world, which I'll call the analog world, the bottleneck? Or does it just shift how you spend your time? I think the fact is the real world will always be the bottleneck, right? You cannot replace the real world entirely by... you know, virtual experimentation will always need the real world. The... Vision is that it will, you know, focus where and how you spend your time in the real world such that those experiments that you do do. are high confidence and ones that you know, would be... Backed. by something that is... Computable, as you will. I think it's a very strange world we live in where the real world will always be the bottleneck, is a quote that we all just heard and probably agree with. By talking just to build on all of this now, I mean, the area of biosciences that I am most excited about is… exactly at the frontier of where Ava's last sentence ended, and it's turning the AI around to compute where the most value is, given probability distributions of what you would see if you would look. Guiding experimentation, in other words, and faster computing and cheaper tokens will help us do that better, which basically addresses directly the bottleneck. out how to... tell you or collaborate with you on where the most exciting, interesting, surprising results might be. It's beam forming to save lives. Exactly. I mean, I think the bottleneck, as you're pointing out, Doug, with the exponential reduction in... for tokenization is the data sets. That is, you know, we just saw billions being, [35:00] allocated for life science data sets. The amount of cost to bring in long, deep data of patients, which are hardly exist today. No, you know, you can get electronic health records, but that's not what you want. You want all these other layers of data. I mean, so, you know, remember, Eric pointed out early on that AlphaFold has been the signature contribution. And that was because we had the protein data bank. The data set was all there. All it took was, you know, milking it for what it could do. with AI. Now, we don't have any data set like that. in life science, or in medicine. And so I think that's what's going to turn out to be holding us back from where we could really zoom forward. That's a really, really interesting point. There's a historical analogy here because my team was building, you know, infrastructure inference serving platforms in the 2010s for RNNs, you know, where you needed the label data to train the models. So data were the bottleneck. And so we were building good models. But then when the Transformer put those pieces together, and you could just train on unlimited amount of text without labeling, It just turned the problem from a data problem into a supercomputing problem. and just said, okay, how big a computer can we build? And of course, cause major platform changes. Do you think a breakthrough like that might be possible in the biospace as well? Because right now we're data limited to your point, but we were in the same situation in 2016. And then boom, this crazy thing happened. Thank you. Well, certainly, I mean, there have been opportunistic leveraging of data sets like the genomic data sets, like the nucleic acid data sets, which are providing new kinds of predictive models, not based necessarily, for example, in protein sequences, but also in looking at the nucleic acids and nucleic acid library. showing some surprising utility. In medicine, it's interesting to think about, like, you know, if we had – an Aladdin's lamp and we could ask for certain forms of data of the clinical type or that go from that link phenotypic clinical data down to, you know, sort of sequence level information about a patient of their, you know, their DNA and their expression, someone of proteins. What is the nature of that data we would ask for and how would we harness it to just think out of the box, you know, and you're the interviewer. I don't want to ask Abba that question, Doug, but I'd love to hear if you had your magic wand. You can say, I learned data of this type that I don't have for data. but either self-supervised training or supervised training, what would I ask for? You get only three gigantic databases to choose from, to ask about. Yeah, so I'll draw a comparison to the Alpha Fold and the PDB example, right? There, it the answer was spot on, right? We saw that breakthrough because the PDB exists. And yet... It is limited because these are static structures of proteins and we know that proteins are dynamic and they're active, right? They execute function through activity. And so I think the real missing thing is these kind of activity first things. data sets for different layers of the biological stack. One Proteins are an easy example. Can we create this same scale and diversity of data mapping protein sequence to function across a range of functions? Historically in the field, there are isolated datasets here and there, they're not really scaled. How can we creatively leverage what's out there, but? Are there new spaces? And we do know there are new spaces in just protein biology as a whole, where we can actually go out and create first in class activity based data sets. And I think that's also. even more true perhaps on the cellular level as well. There was a comment about there are so many different cell types in the human body. We cannot comprehensively map what every single cell type is. will respond to every possible chemical perturbation that exists because the spaces are just... too, too vast, especially in chemical space. But if we're intelligent and principled about [40:00] how what spots of that space we choose to construct a diverse data set, that's also missing. And so I would say this kind of, functional readouts of biology. whether that's on the molecular level or the cellular level or the tissue level, are really what's missing. And in our ex vivo collaboration, we're tackling part of this in the context of cancer cell development, um, cancer cell measurements, looking at trying to build what we call state to function maps that look at a spectrum of cancer cell states and measure functional outcomes. For example, resistance to immunotherapy or resistance to a targeted therapy and resistance. tried to build these bridges but that's just one slice of it and i think more of that same ethos of functional readouts of biology is is 100% what I would go to first. Mm-hmm. Eric Topol, over to you for a sec. We had a pretty broad range discussion. What are a few of the things right now that are just where you think people are listeners need to pay attention what's What are some things you've seen recently that are super exciting? I want to do this around the horn, and then I want to bring us around with a, you know, go a little crazy at the end. I'm going to ground us, and then I'm going to go wild. Well, you know, I think the missing layer in humans is the immune system. the immuno. And everything we've learned to date points to that as a critical underpinning of the health span. So, We need to get to that. We actually published a piece in Nature today about the immunom. Congratulations. you know, quickly, meaningfully get an assessment, whether that's AI of the thymus gland, which had been previously thought goes into involution inert mode by age 20. And now we know at age 80, some people have a perfectly intact thymus gland. And as back to Ava's point about it can predict cancer immunotherapy response and liability to develop cancer. We also have proteomics the age of a person's immune system relative to their chronological age, and immune cells, cell proteome clock. And we're going to get into a much more granular process. assessment of function. I agree with what we need of these functional which we're sure on. So I think once we get that, that's a layer. It's really going to help us because that immune system, whether it's the vulnerability to cancer or whether it's what's going on in the brain to promote neurodegenerative disease or in the arteries for atherosclerosis, it's central. And we haven't had a way to measure it in people. Which is amazing. And only in an academic lab and living, you know, in 20 people. And that's, you know, that's not what we need. So to take that forward and add that into the models, I think that's going to be a really vital step. Yeah, I'll pop up a level and I'll say that I think – that, we will get more than we expect by pursuing the foundations of aging. And this is, you know, the immune system fits in there, but I think in general we don't understand – Why it is that... Many diseases show up with age. They penetrate. Even genetic lesions like LRRK2, something called LRRK2 transposition for Parkinson's disease, it shows up in the 60s and 70s. But why? Why did the body hold off until then? And then it comes through. For Alzheimer's disease and other, as Eric mentioned, the neurodegenerative diseases typically are age-related. of our dna that defines ourselves and the specialization i'll use your language talk a little bit maybe dip switches turning on and off expression that define cell types literally they're just like ons and offs what happens with those the maintenance of those ons and offs and the coherence and um in with age and it's a big mystery if we could crack some of the foundations more entropy, more chaos. But understand interventions and some causation there. I think we will unlock a number of diseases all at once and how to prevent them. I promise you we will have more entropy. Oh, yeah. I'm sure that's true. Sorry for that. [45:00] And Eric Topol wrote a book called Super Agers. I was watching Eric, not just now. I'm sorry, Eric, I was running into your territory. No, no, not at all. Yeah, it's great, great points. Okay, Ava, what are you excited about? As thinking, as both of them were speaking, I was trying to think of what is the single most thing to be excited about. It's hard to pinpoint one. I would say there's a technical one and a biological one. On the technical side, coming back to our data discussion, I think – Innovations that allow for creative innovation utilization of existing data such that we can turn it into a supercomputing problem, as you as you pointed out, Doug. is something of great interest and excitement for us here and in general in the field because Data exists, right? There are certain classes of data that don't exist, as we talked about, but there is a lot of biological data out there and biological tools out there that we can utilize creatively. to compute on. On the biological front, one thing that we haven't really discussed is new measurement techniques that will be able to link biological modalities in new ways. So making new types of measurements in biological systems that we haven't previously done before and Coming back to this multi scale theme right. that will hopefully allow us to link those layers of the biological hierarchy in new ways and draw meaningful... connections between those layers so that we can get to more of these like meta level areas. outputs and outcomes. And on the kind of higher level. I love both the points about the immunom and Aging as kind of systems level things. you know, phenotypes and readouts to go after. And so that is something that I'm really, really excited about moving away from this, Perhaps overhype on virtual cells and really thinking about systems level phenotypes and phenomena is, I think, tremendously promising. Thank you. So, I've always been fascinated by... You have your set of DNA, and that DNA encodes a program. you know, to build an organism. But the execution of that program, like building the cells and the cells reproduce, and then they specialize and they form systems and then they form functions. I mean, that whole, you know, epigenetic and system, like just the fact that a human brain is encoded in the DNA and not directly, obviously, but indirectly with those rules. Do you ever think... With all of the advances and understanding, and this is maybe my looking way out question, we'll understand those rules. and be able to write genetic programs to form full functioning systems or organisms that don't exist. That just will say, hey, I want a glob of cells that can suck CO2 from the air and then spit out algae into the ocean, and this is an organism that will do it. And here's the DNA sequence that will build that organism through all the specialization of cells and replication, because that that area seems to me to be a whole next level of complexity over like just understanding the pathways in a biological system. But this is all your area, so I'm spitballing here. Do you think we'll get there, or is that just so crazy that – We should not even think about it. Yeah, I think that programmability is kind of the promise, right? Can we do functional design and engineering of biology? through interfaces that make sense to. us as humans, whether that's natural language, whether that's other modalities, even perhaps images, if, you know, we can specify a function visually, could that be executed by a protein rate or through chemistry depictions, all these kinds of notions of programmability. But really what you're talking about, Doug, is the heart of synthetic biology was – driven by this ethos of trying to make life programmable and operate and design genetic circuits that could execute functions in living matter just like we engineer Electrical circuits. as the basis of computing and, um, Thank you. It's very nostalgic for me in a way because in undergrad... This was my reason. [50:00] Oh, I didn't know that. So actually, I think you would appreciate this. We were trying to implement state machines in E. coli bacteria by creating these genetic circuits that would respond to different orders and combinations of genes. chemical inputs and these were just kind of a toy example, but the principle is bringing a computational paradigm into a living system and doing, designing an actual circuit in DNA that could, enabled the cell to execute that function. And it's astounding to see how far we've come to now being able to think of, you know, specifying a protein's function in natural language and, you know, having an AI model that could design 100 candidates that would meet that function. And so I think that's like a Uh, A longstanding – vision of biology and it's kind of gone through these Different, I guess, what's the word? Paradigms. If you will, of how we actually get there. So it's a great perspective on the field over the past couple of decades. Even small circuits, like adding to human cells, just a system that would count their generation number. So you can read off, is this a thousand or just four? Is it a cancer? A number, digital. Eric, Topal, I think that Eric Horvitz and Ava are arguing for determinism in biology, like we were talking about earlier. I think they just – they're arguing against themselves, which is kind of fun. What do you think? Great ways. Oh, I know. The things that we're seeing recently, you know, like Jason Durie up at UW with being able to do genome editing during embryogenesis in real time. These are things that were inconceivable a year or two ago, maybe even a month ago. So no, I do think we're going to unravel that aspect of programming that we have so many advanced methods. And, you know, with the analytics capability that's unsurpassed and will keep getting better. So, yeah, that your idea, the idea of having organisms that would fix our environmental problems has been around for a while. Of course, they have a success, but they were primitive. You know, they were not the kinds of things that we might be seeing in the years ahead. So I hope, in fact, that we'll see them. And I think we will. It's just a matter of when. Yeah. Okay, I think that was kind of my list of questions, but maybe I'll go around the horn starting with Ava and then Eric Horvitz and Eric Tobel for closing thoughts. Like we've had a great discussion on… this crazy area that's moving fast and accelerating. And orders of magnitude more power in the models coming that will accelerate it further. So what would you like to leave our listeners with? Ava, I'll start with you. you know, improved intervention. And the reason I personally got into this space at this intersection of computer science and biology was because I saw computer science as a powerful abstraction system and tool set by which we can understand and design biology. So I think above all, both in the biosciences and in the healthcare space for the viewership to remember that we're trying to advance that tool set for the benefit of... researchers and ultimately patients and the rest of Right. on our planet in kind of the grandest sense. That's awesome. Eric Horvitz? Ten years from now, the average person, the public, will – recognize AI as having led to impressive breakthroughs in healthcare. Um, And this will include... Um, and explicitly named as AI breakthroughs, it'll include transforming a number of fatal cancers into chronic diseases by then and, um, uh, making a headway into, um, um, delaying onset and progression of Alzheimer's disease, among other breakthroughs. So I think there'll be several... [55:00] And those two would be huge accomplishments, and they'll be known as AI breakthroughs. That's great. Eric Topol. Yeah, my optimism extends even beyond that, that we will have the ability to prevent Alzheimer's disease and prevent cancers that we aren't today. And so I'm left with just remarkable optimism about where medicine can go now. And we've identified, we've discussed some of the things that are holding it back, but You can just project that it won't look the same in the years ahead. I hope sooner rather than later. But we eventually will have a medicine of practice that is unrecognizable from today. I'd like to thank all three of you for taking the time out of your busy schedules to join us. I think for our listenership, you know, these are great. a set of people who are doing incredible work on the front lines and time spent away from their research is time spent away from inventing the future. So thank you all for joining and taking the time. I really enjoyed the discussion and just. Being able to sit here with the three of you is a real privilege. Thank you. Thank you. Thank you so much. Thank you all. *music*